Emcure Pharmaceuticals Allots 7,700 Equity Shares Under Employee Stock Option Scheme

Emcure Pharmaceuticals has successfully allotted 7,700 equity shares to eligible employees under its Employee Stock Option Scheme 2013 (Emcure ESOS 2013) on December 16, 2025. The allotment represents the exercise of 7,700 vested options by company employees, demonstrating continued participation in the company's equity incentive program.

Regulatory Approval and Process

The Nomination and Remuneration Committee of the Board of Directors approved the allotment through Resolution by Circulation (No. 4 of 2025-26), which was passed unanimously on December 16, 2025. The decision was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Share Capital Impact

The allotment has resulted in an increase in the company's issued and paid-up share capital. The following table shows the change in share capital structure:

Parameter:	Before Allotment	After Allotment
Number of Equity Shares:	18,95,64,847	18,95,72,547
Face Value per Share:	₹10.00	₹10.00
Total Paid-up Capital:	₹189,56,48,470	₹1,89,57,25,470

The increase represents an addition of 7,700 equity shares, each with a face value of ₹10, resulting in a total capital increase of ₹77,000.

Share Rights and Trading

The newly allotted equity shares will rank pari passu in all aspects with the existing equity shares of the company. This means the new shares carry identical rights including voting rights, dividend entitlements, and other shareholder privileges as the existing shares.

Market Information

Emcure Pharmaceuticals Limited trades on both major Indian stock exchanges with the script symbol EMCURE on NSE and script code 544210 on BSE. The company has informed both exchanges about this allotment as part of its regulatory disclosure obligations under SEBI listing regulations.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.47%	+11.34%	+11.04%	+23.80%	+8.22%	+14.07%

Emcure Pharmaceuticals Limited , a prominent player in the Indian pharmaceutical industry, has announced a significant change in its key managerial personnel. Chetan Sharma, who served as the Company Secretary and Compliance Officer, has submitted his resignation, effective November 24, 2025.

Resignation Details

The company disclosed this information in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. According to the official statement:

Effective Date: Close of business hours on November 24, 2025
Reason: To pursue opportunities outside the organization
Position Vacated: Company Secretary, Compliance Officer, and Key Managerial Personnel

Impact on Corporate Governance

The departure of a Company Secretary is a significant event for any listed company, as this role is crucial for ensuring compliance with various regulatory requirements. The Company Secretary acts as a bridge between the board of directors and other stakeholders, playing a vital role in maintaining good corporate governance practices.

Next Steps for Emcure Pharmaceuticals

While the company has not yet announced a successor, it is expected that Emcure Pharmaceuticals will initiate the process to fill this critical position promptly. The appointment of a new Company Secretary and Compliance Officer will be essential to maintain the company's regulatory compliance and corporate governance standards.

Official Disclosure

The resignation was officially communicated through a regulatory filing signed by Sunil Mehta, Whole-time Director of Emcure Pharmaceuticals Limited. The company has provided the following details as part of its disclosure:

Particular	Information
Reason for change	Resignation to pursue opportunities outside the organization
Date of cessation	Close of business hours on November 24, 2025

Emcure Pharmaceuticals has assured stakeholders that they will keep them informed of any further developments regarding this change in key managerial personnel.